Designer Genomics International

Designer Genomics International was described as a contract research organization focused on conducting clinical trials for pharmaceutical, biotechnology, and companion diagnostics companies. Public materials also indicate it was involved in biotechnology activities centered on mRNA-based solutions and proprietary mRNA/miRNA diagnostic panels for inflammatory and chronic disease assessment. Its named GH-101 study was intended to identify differentially expressed genes associated with chronic diseases including cardiovascular disease, end-stage renal disease, PTSD, and cancer. The company was based in Delray Beach, Florida and worked with external laboratory and research partners on genomics-driven studies. Available corporate-registration evidence indicates the Nevada entity "Designer Genomics International Corporation" was revoked in 2024, so the company does not appear to be currently active.